Prothena Corporation plc (PRTA)
Automate Your Wheel Strategy on PRTA
With Tiblio's Option Bot, you can configure your own wheel strategy including PRTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PRTA
- Rev/Share 2.5626
- Book/Share 8.1312
- PB 0.6223
- Debt/Equity 0.0233
- CurrentRatio 9.0009
- ROIC -0.2935
- MktCap 272364620.0
- FreeCF/Share -2.422
- PFCF -2.0892
- PE -2.4701
- Debt/Assets 0.0206
- DivYield 0
- ROE -0.2161
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | PRTA | BofA Securities | Neutral | Underperform | -- | $4 | May 28, 2025 |
| Downgrade | PRTA | Cantor Fitzgerald | Overweight | Neutral | -- | -- | May 27, 2025 |
| Downgrade | PRTA | Jefferies | Buy | Hold | -- | $6 | May 27, 2025 |
| Downgrade | PRTA | Oppenheimer | Outperform | Perform | -- | -- | May 27, 2025 |
| Initiation | PRTA | Chardan Capital Markets | -- | Buy | -- | $40 | Dec. 20, 2024 |
News
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Negative
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Read More
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
Read More
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Negative
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
Read More
Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Emma Seymour - Piper Sandler Jay Olson - Oppenheimer Umer Raffat - Evercore Charles Duncan - Cantor Fitzgerald Jason Butler - Citizens JMP Michael Yee - Jefferies Rudy Li - Chardan Tazeen Ahmad - Bank of America Brian Abrahams - RBC …
Read More
Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm
Published: February 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Read More
About Prothena Corporation plc (PRTA)
- IPO Date 2012-12-18
- Website https://www.prothena.com
- Industry Biotechnology
- CEO Dr. Gene G. Kinney Ph.D.
- Employees 163